LIMMATECH BIOLOGICS
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company.
LIMMATECH BIOLOGICS
Industry:
Biopharma Biotechnology
Status:
Active
Contact:
+41 44 733 8585
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Mologen AG
Mologen AG is an internationally operating bio pharmaceutical company.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-05 | GlycoEra | LimmaTech Biologics investment in Series A - GlycoEra | 45 M CHF |
More informations about "LimmaTech Biologics"
LimmaTech Biologics AG | Home
LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development.See details»
Company | LimmaTech Biologics AG
Led by a team with decades of vaccine development and manufacturing experience and backed by leading investment funds, LimmaTech is rapidly expanding its pipeline to deliver innovative vaccines that combat the …See details»
LimmaTech Biologics AG - LinkedIn
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to...See details»
Valneva and LimmaTech Enter into a Strategic Partnership to …
Aug 1, 2024 · LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical …See details»
LimmaTech Biologics Raises $37 Million Series A to Advance Its …
Schlieren (Zurich), October 9, 2023 - LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM …See details»
CARB-X funds LimmaTech Biologics AG to develop a vaccine that …
(BOSTON: February 27, 2024) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$2.2 million to LimmaTech Biologics AG to advance the …See details»
GSK Grants LimmaTech Biologics License to Develop …
Jul 20, 2023 · LimmaTech Biologics AG is applying its deep know-how of engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases.See details»
LimmaTech Biologics AG - Swiss Biotech
LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to …See details»
LimmaTech Biologics Expands Vaccine Pipeline by
Dec 19, 2023 · LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development.See details»
LimmaTech Biologics - Crunchbase Investor Profile
LimmaTech Biologics received an additional $3 million in Series A funding, bringing the total amount raised to $40 million.See details»
LimmaTech Biologics Adds Additional $3 Million in Series A …
Feb 1, 2024 · LimmaTech is committed to providing solutions against increasingly dangerous infections, with specific programs addressing Staphylococcus aureus, Shigella, and sexually …See details»
LimmaTech Biologics: USD 37 million for vaccines against …
Oct 9, 2023 · LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo …See details»
LimmaTech and Valneva: Partnership for Shigella vaccine
Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline; LimmaTech to …See details»
Pipeline & Clinical Trials | LimmaTech Biologics AG
Since its foundation in 2015, LimmaTech has evaluated candidate vaccines in several clinical trials in locations around the world. LimmaTech Biologics AG is committed to combating AMR …See details»
Shigella - S4V2 - Valneva
Shigella4V2 (S4V2) is a tetravalent bioconjugate vaccine candidate against shigellosis. Valneva in-licensed S4V2 as part of an exclusive worldwide development, manufacturing, and …See details»
LimmaTech Biologics Raises $37 Million Series A to Advance Its …
Oct 9, 2023 · LimmaTech Biologics AG is applying its deep know-how of engineering complex molecules to develop next-generation vaccines to prevent life-threatening diseases.See details»
LimmaTech Biologics Expands Vaccine Pipeline by Licensing …
Dec 19, 2023 · SCHLIEREN, Switzerland & ROCKVILLE, Md., December 19, 2023 -- (BUSINESS WIRE)-- LimmaTech Biologics and AbVacc announced today a license agreement that grants …See details»
LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead …
Jul 20, 2023 · LimmaTech Biologics AG is applying its deep know-how of engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases.See details»
LimmaTech Biologics announces the start of a Phase I/II trial of a ...
Schlieren (Zurich), 8 July 2021 - LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Germany of a 4-valent candidate vaccine to help prevent Klebsiella …See details»
LimmaTech Biologics announces the start of a Phase I/II trial of a ...
Jul 8, 2021 · LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Germany of a 4-valent candidate vaccine to help prevent Klebsiella infections. LimmaTech is …See details»